AXIOMATIC-SSP: Reducing risk of ischaemic stroke with factor XIa inhibition?

Late-breaking findings from the phase 2, dose-ranging AXIOMATIC-SSP trial evaluating milvexian for secondary stroke prevention showed that, although dose response was not observed, there appeared to be benefit for symptomatic ischaemic strokes. Overall safety appeared reassuring. Milvexian is a small molecule inhibitor that binds activated factor XI with high affinity and selectivity and may reduce the risk of stroke when added to antiplatelet drugs without significant bleeding. Because genetic variants known to reduce factor XI levels are associated with reduced risk for ischaemic stroke but are not associated with increased intracranial bleeding, the rationale behind the AXIOMATIC-SSP trial (NCT03766581) was to target factor XI. In the trial, presented by Dr Mukul Sharma (McMaster University, Canada), participants with a mild-to-moderate acute non-lacunar ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 27 October, 202226 October, 2022